Used in oncology research as a potent inhibitor of poly(ADP-ribose) polymerase (PARP), particularly targeting tumors with defects in DNA repair pathways. Shows potential in overcoming resistance to earlier PARP inhibitors, making it valuable in studies involving BRCA-mutated and other homologous recombination-deficient cancers. Investigated for its ability to enhance the effects of DNA-damaging agents like chemotherapy and radiation in preclinical models. Currently limited to experimental use and not approved for clinical treatment.